Weight loss revolution: noom teams up with GLP-1 drugs in massive new study
NCT ID NCT07588984
First seen May 17, 2026 · Last updated May 23, 2026 · Updated 2 times
Summary
This study will test if combining GLP-1 medications (like semaglutide and tirzepatide) with Noom's digital health program helps people with obesity lose weight and improve health markers like blood sugar and cholesterol. About 2,310 adults will be followed for 24 months. The goal is to see if this approach is more effective than education alone or Noom without medication.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for WEIGHT LOSS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Noom, Inc.
Princeton, New Jersey, 08542, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.